Therapie der Mukoviszidose – neue Medikamente geben Hoffnung

Was ist neu?

Therapieansatz Bis vor kurzem bestand die medikamentöse Therapie der Mukoviszidose nur aus einer rein symptomatischen Therapie, aber der Defekt des Chloridkanals konnte nicht beeinflusst werden. Mit der CFTR-Modulatortherapie besteht nun erstmals eine ursächliche und effiziente Therapie, die eine Verbesserung der Lungenfunktionswerte erzielt wie keine der bisherigen Therapien.

Abstract

For decades there were only symptom-oriented therapies for the monogenetic disease cystic fibrosis. With the new modulator therapies there are new hopes to better influence the course of the disease, which has its manifestation in several organs such as the lungs, the liver or pancreas.

In addition to ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor, a triple combination with elexacaftor/tezacaftor/ivacaftor was developed. Studies in F508del homozygous and heterozygous patients with cystic fibrosis have resulted in significant clinical improvement and have therefore been approved by the FDA for the first time in the USA.

The results are very promising as already after 4 weeks a significant improvement of FEV1 and a significant decrease of the sweat chloride content could be detected. In the USA all patients with at least one F508del mutation can be prescribed the drug. This corresponds to approximately 90 % of all patients with cystic fibrosis and has the potential to change the landscape of cystic fibrosis.

Schlüsselwörter

Mukoviszidose - Multiorganerkrankung - CFTR-Modulatortherapie

Key words

cystic fibrosis - multiorgan disease - CFTR-modulator therapy

• Literatur

• 1 Fanconi G, Uehlinger E, Knauer C. Das Coeliakie-syndrom bei angeborener zystischer Pankreasfibromatose und Bronchiektasien. Wien Med Wochenschr 1936; 86: 753-756
• 2 Kerem B, Rommens J, Buchanan J. et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080
• 3 Elborn JS. Cystic fibrosis. Lancet 2016; 388: 2519-2531
• 4 Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: Onset and Etiology. Pediatr Pulmonol 1997; 24: 137-142
• 5 Ratjen F, Hartog CM, Paul K. et al. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002; 57: 930-934
• 6 Döring G, Flume P, Heijerman H. et al. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros 2012; 11: 461-479
• 7 Staab D, Schwarz C. Zystische Fibrose. Internist (Berl) 2018; 59: 1138-1145
• 8 Schwarz C, Staab D. Zystische Fibrose und ihre Komplikationen. Internist 2015; 56: 263-274
• 9 Jain R, Mall M, Dřevínek P. et al Phase 3 efficacy and safety of the ELX/TEZ/ iva triple combination in people with CF and F508del/minimal function genotypes. Nashville: North American Cystic Fibrosis Conference. TN 2019; Poster 507
• 10 Middleton PG, Mall MA, Dřevínek P. et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381: 1809-1818
• 11 Ridley K, Condren M. Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. J Pediatr Pharmacol Ther 2020; 25: 192-197